Price Alert

BioCryst Pharmaceuticals ... (BCRX)

NASDAQ: BCRX · Real-Time Price · USD

8.39

-0.06 (-0.71%)

At close: Aug 15, 2025, 12:49 PM

BioCryst Pharmaceuticals Statistics

Share Statistics

BioCryst Pharmaceuticals has 209.92M shares outstanding. The number of shares has increased by 1.14% in one year.

Shares Outstanding	209.92M
Shares Change (YoY)	1.14%
Shares Change (QoQ)	0.14%
Owned by Institutions (%)	81.47%
Shares Floating	202.2M
Failed to Deliver (FTD) Shares	315
FTD / Avg. Volume	0.01%

Short Selling Information

The latest short interest is 26.78M, so 12.8% of the outstanding shares have been sold short.

Short Interest	26.78M
Short % of Shares Out	12.8%
Short % of Float	12.85%
Short Ratio (days to cover)	9.27

Valuation Ratios

The PE ratio is -17.49 and the forward PE ratio is 15.38. BioCryst Pharmaceuticals's PEG ratio is 0.28.

PE Ratio	-17.49
Forward PE	15.38
PS Ratio	3.45
Forward PS	2.6
PB Ratio	-3.27
P/FCF Ratio	-29.25
PEG Ratio	0.28

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for BioCryst Pharmaceuticals.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 2.63, with a Debt / Equity ratio of -1.77.

Current Ratio	2.63
Quick Ratio	2.58
Debt / Equity	-1.77
Debt / EBITDA	65.69
Debt / FCF	-15.83
Interest Coverage	-0.03

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$777.09K
Profits Per Employee	$-153.24K
Employee Count	580
Asset Turnover	0.92
Inventory Turnover	1.52

Taxes

Income Tax	1.93M
Effective Tax Rate	-2.22%

Stock Price Statistics

The stock price has increased by 6.08% in the last 52 weeks. The beta is 1.1, so BioCryst Pharmaceuticals's price volatility has been higher than the market average.

Beta	1.1
52-Week Price Change	6.08%
50-Day Moving Average	9.37
200-Day Moving Average	8.42
Relative Strength Index (RSI)	42.73
Average Volume (20 Days)	3,850,562

Income Statement

In the last 12 months, BioCryst Pharmaceuticals had revenue of 450.71M and earned -88.88M in profits. Earnings per share was -0.43.

Revenue	450.71M
Gross Profit	438.44M
Operating Income	-2.54M
Net Income	-88.88M
EBITDA	12.81M
EBIT	11.56M
Earnings Per Share (EPS)	-0.43

Full Income Statement

Balance Sheet

The company has 104.71M in cash and 841.42M in debt, giving a net cash position of -736.71M.

Cash & Cash Equivalents	104.71M
Total Debt	841.42M
Net Cash	-736.71M
Retained Earnings	-1.77B
Total Assets	457.19M
Working Capital	221.3M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -52.02M and capital expenditures -1.12M, giving a free cash flow of -53.14M.

Operating Cash Flow	-52.02M
Capital Expenditures	-1.12M
Free Cash Flow	-53.14M
FCF Per Share	-0.26

Full Cash Flow Statement

Margins

Gross margin is 97.28%, with operating and profit margins of -0.56% and -19.72%.

Gross Margin	97.28%
Operating Margin	-0.56%
Pretax Margin	-19.29%
Profit Margin	-19.72%
EBITDA Margin	2.84%
EBIT Margin	-0.56%
FCF Margin	-11.79%

Dividends & Yields

BCRX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for BCRX is $16, which is 95.1% higher than the current price. The consensus rating is "Buy".

Price Target	$16
Price Target Difference	95.1%
Analyst Consensus	Buy
Analyst Count	11

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-2.62
Piotroski F-Score	3